Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc (NASDAQ: MBOT) is a pioneer in micro-robotic medical technologies focused on revolutionizing minimally invasive procedures. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in developing autonomous surgical platforms like the LIBERTY Robotic System and Self-Cleaning Shunt technology.
Discover comprehensive coverage of MBOT's latest press releases, including clinical milestones, regulatory updates, and strategic partnerships. Our curated news collection serves as a centralized resource for tracking advancements in robotic-assisted interventions designed to reduce surgical trauma and improve patient outcomes.
Key updates include developments in patented micro-robotic platforms, financial performance reports, and innovations addressing complex surgical challenges. Bookmark this page to stay informed about MBOT's progress in creating next-generation tools that aim to transform vascular and endoscopic procedures through precision robotics.
Microbot Medical (NASDAQ: MBOT) has announced the appointment of Professor Gerry O’Sullivan to its Scientific Advisory Board, enhancing its EU presence as it prepares for human clinical trials of the LIBERTY® Robotic System. With over 25 years of experience in interventional radiology, Professor O’Sullivan brings expertise in venous disease treatments. His involvement is expected to bolster innovation and execution of commercialization strategies. This comes amid increasing global interest in the LIBERTY system, designed to address the needs of interventional radiologists.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) with the appointment of Professor Mark W. Little, a distinguished academic leader from the UK. Professor Little will collaborate with other experts to enhance the regulatory and commercialization efforts for the LIBERTY Robotic System, the first single-use endovascular robotic device. Having significant experience in interventional radiology, he has previously participated in studies on the LIBERTY system and expressed confidence in its potential impact on the market. This addition signals a strengthening of the company’s clinical expertise and reinforces its strategic goals.
Microbot Medical (Nasdaq: MBOT) announced on March 13, 2023, that Dr. Stavros Spiliopoulos has joined its Scientific Advisory Board. As an internationally recognized interventional radiologist, Dr. Spiliopoulos's expertise will bolster the company's efforts to advance the LIBERTY® Robotic System towards regulatory approval and commercialization. His extensive experience in vascular interventional radiology and numerous awards further solidify his role. The addition reflects Microbot's ongoing strategy to enhance clinical awareness and establish centers of excellence in key growth markets in Europe and the Americas.
Microbot Medical (Nasdaq: MBOT) has announced that an abstract detailing the LIBERTY Robotic System will be presented at the Israeli Conference on Robotics on March 28, 2023. Dr. Eyal Morag, the company's Chief Medical Officer, will discuss the advantages of this single-use endovascular robotic system over traditional methods, highlighting reduced physician radiation exposure and physical stress. The presentation will include findings from animal feasibility studies showcasing performance and safety metrics. The conference serves as a major event for robotics advancements across various sectors, including healthcare.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
